Hospira Spin-Off From Abbott "Progressing Smoothly," CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Under a Transition Services Agreement, Abbott will sell Hospira products abroad until the hospital company develops an international infrastructure. Hospira expects three product launches in 2005.
You may also be interested in...
Hospira Spins Off With $4.2 Bil. Market Cap; Abbokinase Stays With Abbott
Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.